Results 91 to 100 of about 4,025 (198)

Partial Courses of Fidaxomicin Followed by Oral Vancomycin and the Effect on Recurrence of Clostridioides difficile Infections [PDF]

BACKGROUND: Clostridioides difficile infection (CDI) causes a significant national health care burden. Literature has demonstrated lower rates of CDI recurrence with fidaxomicin compared with oral vancomycin.
Ahmad, Zayd, Kamrada, Meghan, Lockhart, Ellen R, Everson, Nathan, Stornelli, Nicholas, McDaniel, Lauren, Papamanolis, Irene-Constantina   +6 more
core   +3 more sources

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

, 2011
A 10-day course of oral fidaxomicin (200 mg twice a day [b.i.d.]), a potent new macrocyclic drug, was compared to vancomycin (125 mg four times a day [q.i.d.]) in 1,164 adults (1,105 in the modified intent-to-treat [mITT] population) with ...
Ellie J. C. Goldstein, Farah Babakhani, Pamela Sears, Susan P. Sambol, Dale N. Gerding, Diane M. Citron   +5 more
core   +1 more source

Improving fidaxomicin production through ARTP mutagenesis and fermentation optimization in Actinoplanes deccanensis

Synthetic and Systems Biotechnology
Fidaxomicin, a macrolide antibiotic, is widely used to treat Clostridioides difficile infection (CDI). It demonstrats significantly higher clinical efficacy than vancomycin and metronidazole. However, the large-scale industrial production of it remains a
Jing-Yi Ruan, Huang Xie, Yi-Lei Zheng, Qing-Wei Zhao, Xin-Ai Chen, Zhong-Yuan Lyu, Yong-Quan Li   +6 more
doaj   +1 more source

The environmental stress σ subunits render M. tuberculosis RNA polymerase resistant to fidaxomicin by restricting its binding pocket conformational plasticity

Fidaxomicin is a narrow-spectrum antibiotic that inhibits bacterial RNA polymerase (RNAP) at an early stage of transcription initiation. Fidaxomicin is used for treating Clostridioides difficile infections and has demonstrated in vitro efficacy against ...
Laurent Chaloin, Ondine Duverger, Stéphanie Norsikian, Konstantin Brodolin, Zakia Morichaud, Emmanuel Roulland   +5 more
core   +1 more source

SARS‐CoV‐2 PLpro Inhibition: Evaluating in Silico Repurposed Fidaxomicin's Antiviral Activity Through In Vitro Assessment

ChemistryOpen
The emergence of drug‐resistant viruses and novel strains necessitates the rapid development of novel antiviral therapies. This need was particularly demanding during the COVID‐19 pandemic.
B.Sc. Sara Protić, M.Sc. Milica Crnoglavac Popović, M.Sc. Nevena Kaličanin, Dr. Olivera Prodanović, Dr. Milan Senćanski, Dr. Jelena Milićević, Dr. Kristina Stevanović, Dr. Vladimir Perović, Dr. Slobodan Paessler, Dr. Radivoje Prodanović, Dr. Sanja Glišić   +10 more
doaj   +1 more source

Evaluating Bezlotoxumab-Fidaxomicin Combination Therapy in Clostridioides Infection: A Single-Center Retrospective Study from Aichi Prefecture, Japan

Antibiotics
Background/Objectives: Clostridioides difficile infection (CDI) poses a significant healthcare challenge, with recurrence rates reaching 30%, leading to substantial morbidity and costs.
Jun Hirai, Nobuaki Mori, Yuki Hanai, Nobuhiro Asai, Mao Hagihara, Hiroshige Mikamo   +5 more
doaj   +1 more source

Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

Infection and Drug Resistance, 2017
Amanda R D’Ostroph,1 Tsz-Yin So2 1UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, 2Department of Pharmacy, Moses H Cone Memorial Hospital, Greensboro, NC, USA Abstract: The incidence of Clostridium ...
D'Ostroph AR, So TY
doaj  

A Review of Therapies for Clostridioides difficile Infection

Antibiotics
Clostridioides difficile is an urgent public health threat that affects approximately half a million patients annually in the United States. Despite concerted efforts aimed at the prevention of Clostridioides difficile infection (CDI), it remains a ...
Faiza Morado, Neha Nanda
doaj   +1 more source

Antimicrobial Susceptibility of Clostridioides difficile in Spain: Multicenter Retrospective Cohort Study

Antibiotics
Background/Objetives: The objective of this study was to determine the in vitro susceptibility profiles of clinical Clostridioides difficile isolates to metronidazole (MTZ), vancomycin (VAN), fidaxomicin (FDX), tigecycline (TGC), and eravacycline (ERV ...
María-Paz Ventero, María-Dolores Valverde-Fredet, Esperanza Merino, Rocío Herrero, Iryna Tyschkovska Germak, Miguel Rodríguez-Fernández, Jose-Manuel Ramos-Rincón, Maria Garcia, Elisabet Delgado-Sánchez, Miguel Nicolás Navarrete-Lorite, Concepcion Gil, María Tasias, Juan Jose Caston, David Vinuesa-Garcia, Cristina Gomez-Ayerbe, Francisco J. Martínez Marcos, Nicolas Merchante, Juan Carlos Rodríguez   +17 more
doaj   +1 more source

Reshaping Natural Products: New Fidaxomicin Antibiotics and Darobactin-Like Peptides

This thesis is structured into two chapters which detail different approaches for the optimisation and mimicry of natural products. The first chapter covers the development of new antibiotic derivatives based on the natural product fidaxomicin.
Jung, Erik
core